What is Zacks Research’s Forecast for Prothena Q1 Earnings?

Prothena Co. plc (NASDAQ:PRTA) – Investment analysts at Zacks Research boosted their Q1 2025 earnings estimates for shares of Prothena in a report issued on Wednesday, March 12th. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will earn ($1.06) per share for the quarter, up from their prior estimate of ($1.33). The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share. Zacks Research also issued estimates for Prothena’s Q2 2025 earnings at ($1.11) EPS, Q3 2025 earnings at ($1.11) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($3.76) EPS, Q1 2026 earnings at ($1.27) EPS, Q2 2026 earnings at ($1.18) EPS, Q3 2026 earnings at ($1.28) EPS, Q4 2026 earnings at ($0.31) EPS and FY2026 earnings at ($4.04) EPS.

Other analysts also recently issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $48.00 price target on shares of Prothena in a research report on Friday, February 21st. Chardan Capital reissued a “buy” rating and set a $40.00 price target on shares of Prothena in a research report on Friday, February 21st. Oppenheimer boosted their price target on shares of Prothena from $58.00 to $62.00 and gave the company an “outperform” rating in a report on Friday, February 7th. StockNews.com upgraded Prothena from a “sell” rating to a “hold” rating in a report on Monday, February 24th. Finally, Piper Sandler increased their price target on Prothena from $94.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Prothena currently has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Prothena Stock Performance

Shares of PRTA opened at $13.74 on Monday. The stock has a market cap of $739.58 million, a P/E ratio of -5.97 and a beta of -0.02. Prothena has a 1 year low of $11.70 and a 1 year high of $26.75. The stock’s 50-day moving average price is $14.41 and its two-hundred day moving average price is $16.04.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.06). Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The business had revenue of $2.12 million during the quarter, compared to analyst estimates of $7.53 million.

Institutional Investors Weigh In On Prothena

Large investors have recently added to or reduced their stakes in the business. Virtus ETF Advisers LLC boosted its holdings in shares of Prothena by 19.3% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company’s stock worth $71,000 after buying an additional 833 shares during the period. Headlands Technologies LLC lifted its position in Prothena by 196.5% during the fourth quarter. Headlands Technologies LLC now owns 7,330 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 4,858 shares during the last quarter. Teacher Retirement System of Texas bought a new stake in shares of Prothena during the fourth quarter worth approximately $145,000. Purkiss Capital Advisors LLC acquired a new position in shares of Prothena in the fourth quarter valued at approximately $149,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Prothena by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 1,065 shares during the period. Institutional investors own 97.08% of the company’s stock.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.